Navigation Links
Genelabs Technologies to Present at the BIO CEO & Investor Conference

REDWOOD CITY, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. (Nasdaq: GNLB) announced today that its Chief Financial Officer Fred Driscoll will present a company update at the BIO CEO Investor Conference at the Waldorf Astoria Hotel Tuesday, February 12, 2008 at 2:00 pm E.T.

The presentation is scheduled to be webcast live and may be accessed by going to the Investor Information section of the Genelabs website at or through the following URL: 37 The presentation will also be available for replay after the presentation for a limited time.

About Genelabs Technologies

Genelabs Technologies, Inc. is a biopharmaceutical company focused on the discovery and development of pharmaceutical products to improve human health. We have built drug discovery capabilities that can support various research and development projects. Genelabs is currently concentrating these capabilities on discovering novel compounds that selectively inhibit replication of the hepatitis C virus and advancing preclinical development of compounds from this hepatitis C virus drug discovery program. We also have late-stage products for hepatitis E virus and lupus. We believe that these high-risk, potentially high reward programs focus our research and development expertise in areas where we have the opportunity to generate either first-in-class or best-in-class products that will address diseases for which current therapies are inadequate. For more information, please visit

Note: Genelabs(R) and the Genelabs logo are registered trademarks of Genelabs Technologies, Inc.

Contact: Frederick W. Driscoll

Chief Financial Officer

Phone: 650-562-1424

SOURCE Genelabs Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genelabs Technologies, Inc. Announces Resignation of President and CEO
2. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
3. Netsmart Technologies Extends Relationship with Manatee Glens for Enterprise Behavioral Health Software Solutions
4. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
5. Guava Technologies Celebrates Tenth Anniversary
6. BioSpecifics Technologies Corp. Announces Repayment of Outstanding Loan
7. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
8. Intrasphere Technologies Releases PharmaCM Submissions Management and Authoring Module Powered by Microsoft Office SharePoint Server 2007
9. Neurobiological Technologies Sets Date for Second Quarter Financial Results
10. Emisphere Technologies to Present at BIO CEO & Investor Conference on February 12
11. Vestibular Technologies Is Awarded Contract by Major Group Purchasing Organization (GPO)
Post Your Comments:
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) holds ... organisation (CRO) market. The trend of outsourcing to ... margins but higher volume share for the region ... scale, however, margins in the CRO industry will ... Market ( ), finds that the ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is an essential ... bound to proteins, copper is also toxic to cells. With a $1.3 million ... (WPI) will conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... This fall, ... at competitive events in five states to develop and pitch their BIG ideas to ... from each state are competing for votes to win the title of SAP's Teen ...
Breaking Biology Technology:
(Date:11/17/2015)... 2015 Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" ... sale of broadly enabling, pressure cycling technology ("PCT")-based sample ... announced it has received gross proceeds of $745,000 from ... (the "Offering"), increasing the total amount raised to date ... closings are expected in the near future. ...
(Date:11/12/2015)... Nov. 12, 2015  Arxspan has entered into ... and Harvard for use of its ArxLab cloud-based ... tools. The partnership will support the institute,s efforts ... chemical research information internally and with external collaborators. ... for managing the Institute,s electronic laboratory notebook, compound ...
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
Breaking Biology News(10 mins):